Mast Therapeutics, Inc. Short InterestMSTX $0.415* 0.004 0.95%Get MSTX Alerts
*Delayed - data as of Aug. 30, 2013 Exchange: AMEX
Industry: Health Care
Community Rating: Strong sell
Settlement Date Short Interest Avg Daily Share Volume Days To Cover 8/15/2013 4,551,893 905,601 5.026378 7/31/2013 4,357,204 1,909,532 2.281818 7/15/2013 4,118,450 1,400,537 2.940622
Read more: http://www.nasdaq.com/symbol/mstx/short-interest#ixzz2dfc1ULYG
MSTX Composite Indicators Signal
Short Term Indicators
7 Day Average Directional Indicator Sell
10 - 8 Day Moving Average Hilo Channel Hold
20 Day Moving Average vs Price Sell
20 - 50 Day MACD Oscillator Sell
20 Day Bollinger Bands Hold
Short Term Indicators Average: +60.00%% Sell
20-Day Average Volume - 732
Medium Term Indicators
40 Day Commodity Channel Index Sell
50 Day Moving Average vs Price Sell
20 - 100 Day MACD Oscillator Sell
50 Day Parabolic Time/Price Sell
Medium Term Indicators Average: +100.00%% Sell
50-Day Average Volume - 561
Long Term Indicators
60 Day Commodity Channel Index Sell
100 Day Moving Average vs Price Sell
50 - 100 Day MACD Oscillator Sell
Long Term Indicators Average: +100.00%% Sell
100-Day Average Volume - 536
Overall Average: +88.00%% Sell
Average to consider is .25 cents
Sentiment: Strong Sell
When the short interest goes up that much is when you want to buy since the PPS is low and now MSTX is oversold. It is when the short interest gets covered after the short squeeze resulting in a major bounce that you sell.
DUH !!! If your to dumb to know that kind of stuff you should not be investing in stocks.
As part of the company's April 2011 acquisition of SynthRX, the company gained control of MST-188. MST-188 is a purified form of a nonionic, triblock copolymer (P188). It is an investigational agent that binds to hydrophobic surfaces on damaged cells and improves membrane hydration and lowers adhesion and viscosity, particularly under low shear conditions. Research has demonstrated that P188 prevents adhesion and aggregation of soluble fibrin and formed elements in the blood and maintains the deformability of red blood cells, the non-adhesiveness of unactivated platelets and granulocytes and the normal viscosity of blood. MST-188 has the potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions.
Sickle Cell Disease
Sickle cell disease is an inherited blood disorder in which red blood cells contain an abnormal type of hemoglobin and frequently take on a sickle- or crescent-shape. These defective red blood cells can block small blood vessels, which can lead to tissue damage or even stroke. Other complications include anemia, jaundice, gallstones, severe leg and arm pain, and spleen, liver and kidney damage.
In a recent University of Florida study, researchers evaluated data from the Florida Medicaid program on 4,294 sickle cell patients. The study found that the annual cost of medical care in the US for people who suffer from sickle cell disease exceeds $1.1 billion. Roughly 80% of the costs were associated with inpatient care; 3.2% of costs were associated with emergency department (ED) use, 0.9% with physician visits, and 3.6% with prescription drugs. The remaining 11.7% of costs were attributed to various forms of care, to include home health and nursing home care.
Currently, treatment for sickle cell anemia is usually aimed at avoiding crises, relieving symptoms, and preventing complications. Bone marrow transplants offer the only cure for SCD, but this is an expensive, difficult procedure with significant risk. Other treatments may include medications to reduce pain and prevent complications, blood transfusions, and supplemental oxygen. Hydroxyurea has been found to be effective in reducing the frequency of painful episodes in adults with SCD, but is not useful as a treatment for patients who are experiencing an acute painful episode, nor is it approved for use in children. During the past 25 years, a number of pharmacological agents have been evaluated as potential intervention strategies that might be capable of shortening or reducing the severity of painful episodes; yet each of these therapies has been found to be either too toxic or only marginally effective.
Some DD information for the thoughtful investor...
One of the most exciting biotechnology companies in the market today is Mast Therapeutics (MSTX), a little known company developing an Orphan designated investigational agent (MST-188) that has potential to reduce ischemic tissue injury and end organ damage by restoring microvascular function. MSTX's current clinical focus is on two Orphan diseases: Sickle Cell Anemia ("SCD") and Acute Limb Ischemia ("ALI"). MSTX has already received Orphan Designation for SCD in the U.S and EU, and for ALI in the EU. The stock currently trades at 30 percent below its cash position, has no debt, and existing financial resources are more than adequate to fund the ongoing Phase 3 study in SCD, Phase 2 study in ALI, as well as additional studies for other indications. With a potential pharmaceutical treatment for multiple medical conditions affecting millions worldwide, MSTX is a significantly undervalued biotech with exponential upside.
Effective March, 2013, Adventrx Pharmaceuticals become known as Mast Pharmaceuticals, taking its name from the acronym (M)olecular (A)dhesion & (S)ealant (T)echnology Platform. In 2009, the majority of business operations were suspended and the workforce was reduced to only two employees. From 2009 to 2011 the company's primary focus was in oncology and the reformulation of drugs previously approved by the FDA. Like many small biotechs, the company's attempts to gain FDA approval for their oncology based drugs proved unsuccessful, and the company instead focused on clinical development of MST-188 for Sickle Cell Anemia (Phase 3) and Acute Limb Ischemia (Phase 2). MST-188 is the most clinically-advanced drug for SCD, and MSTX initiated a Phase 3 study in March 2013. MSTX expects to begin its Phase 2 study for ALI in late Q4 or early Q1 2014. They have received Orphan Designation for MST-188 for SCD in the U.S and EU and for ALI in the EU. Management intends to file for Orphan Designation for ALI in the U.S. later this year.
Sentiment: Strong Buy